Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker    Newsletter   Tax Corner NRI Centre Forums E-Mail Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Hindalco 176.20 3.59
Sslt 282.90 2.07
Tata Stl 523.85 2.01
Bhel 238.60 0.89
Tata Pow 90.05 3.62
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Aurobindo Pharma Limited
Aurobindo Pharma Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs
BSE:524804NSE:AUROPHARMABloomberg:ARBP@INReuters:ARBN.BO
Market Lot: 1Face Value: 1ISIN Demat: INE406A01037
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
01-JUL-14 Aurobindo Pharma, a mid-size pharmaceutical company,announced that Sudhir B Singhi, chief financial officer (CFO) of the company has relinquished his duties due to his personal reasons. 03-JUN-14 indo Pharma, a mid-size pharmaceutical company, announced that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Divalproex Sodium Extended-release Tablets USP 250mg and 500mg. (...   More..
Business Profile Future Plans
CEO Talk
Aurobindo Pharma, plans to complete restructuring and expansion programme during Q4 FY 2001-02. The company plans to achieve a turnover of above Rs 4,000 crore by FY 2005-06 with formulations accounting for 30 per cent. Joint ventures in US and China are expected boost the company`s international revenues.  Srinivas Lanka
One To One
Recent news
Latest News
Aurobindo Pharma names Santhanam Subramanian as CFO  -IRIS 01-Jul-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)30-Jun-2014(3)31-Mar-2014 (12)31-Mar-2013 (12)
Net sales 19345.6070495.7053529.10
Other Income56.90328.70150.10
Total Income19402.5070824.4053679.20
Cost of goods sold13630.1051912.3044670.40
OPBDIT5772.4018912.109008.80
PAT3934.0011720.904959.90
Gross Block---
Equity capital291.50291.50291.20
EPS (Rs.)-40.2417.04
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-3.44 - 13.545.85 - 12.02
Debt / Equity (x)---
Operating margin (% of OI)29.826.716.8
Net margin (% of OI)20.316.5 9.2
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Plot No 2
Maitri Vihar
Ameerpet
Hyderabad
Andhra Pradesh-500 038
PHONE
(040) 6672 5000
FAX
(040) 2374 1080/ 6833
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Trade On-line | Wealth Tracker | Newsletters | Tax Corner | NRI Centre | Forums | E-mail | Chat | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer